Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
- 18 September 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (510)
- https://doi.org/10.1126/scitranslmed.aaw7999
Abstract
Combined targeting of KRAS-G12C, mTOR, and IGF1R enhances and extends the response to recently developed KRAS-G12C inhibitors in lung cancer models.Keywords
Funding Information
- Wellcome (103799/Z/14/Z)
- Wellcome (FC001070)
- H2020 European Research Council (RASTARGET)
- Medical Research Council (FC001070)
- Cancer Research UK (FC001070)
This publication has 55 references indexed in Scilit:
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancersJCI Insight, 2011
- Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perilsEMBO Molecular Medicine, 2011
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerJCI Insight, 2008
- The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1Science, 2008
- Restraining PI3K: mTOR signalling goes back to the membraneTrends in Biochemical Sciences, 2005
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Mammalian Target of Rapamycin Pathway Regulates Insulin Signaling via Subcellular Redistribution of Insulin Receptor Substrate 1 and Integrates Nutritional Signals and Metabolic Signals of InsulinMolecular and Cellular Biology, 2001